EGFR and colonic neoplasm: Compared with the wild-type colon cancer cells, the G13D mutation on KRAS determines a reduction in the responsiveness of LoVo cells to cetuximab and panitumumab, drugs that target the epidermal growth factor receptor (EGFR) [30].